ACC Scientific Statement Outlines Strategies For Earlier Initiation of Lipid-Lowering Therapies
A new ACC Scientific Statement offers a comprehensive set of lipid-lowering strategies for detecting and managing atherosclerotic cardiovascular disease (ASCVD) earlier in life.
Published in JACC, the "Lipid-Lowering Strategies in the Era of Early Atherosclerosis Detection: 2026 ACC Scientific Statement" reviews the latest evidence supporting earlier detection, assessment and treatment and provides a series of consensus recommendations tied to use of risk enhancers, the role of imaging in ASCVD risk, use of combination therapy, and areas of future growth.

Earlier Intervention
"There is a strong rationale for both earlier and longer-term lipid lowering, including intensive lifestyle management and medications, in people with elevated ASCVD risk, especially related to earlier exposure to unfavorable lipid levels," according to Writing Committee Chair Philip Greenland, MD, FACC, et al.
Risk Assessment
They stress that clinicians "should integrate estimated short- and long-term risk, lipid burden, risk enhancers, imaging findings when appropriate, and patient preferences to guide individualized, shared decision making to reduce lifetime ASCVD risk."
Future Research Needs
In addition to strategies that can be implemented now, the Scientific Statement also highlights areas where further research is needed, including among asymptomatic young adults who might benefit from earlier lipid-lowering therapy but don't have a current indication. "Future studies and decision models should focus on individuals without clinical ASCVD to establish effectiveness, safety, adherence, and cost-effectiveness of these interventions."
Clinical Topics: Dyslipidemia, Lipid Metabolism
Keywords: Lipids, Atherosclerosis